Takeovers are also known as mergers and acquisitions. Businesses can gain a competitive advantage with this strategy, and ultimately increase shareholder value.
|
Sage Therapeutics, Inc. – SYM: SAGE Recent Price: $7.03
Takeover Action: Sage Therapeutics announced that Biogen has submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage not already owned by Biogen for $7.22 per share. Description: Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. |
Sonim Technologies, Inc. – SYM: SONM Recent Price: $3.42
Takeover Action: Sonim Technologies announced the formation of a special committee of independent directors to explore and evaluate strategic alternatives to enhance stockholder value. The committee will consider various strategic options, including business combinations such as mergers or acquisitions and other potential transactions, such as selling the company or a significant portion of its assets. Description: Sonim Technologies, Inc. provides ruggedized mobile phones and accessories for task workers. The company offers ruggedized mobile phones, such as Sonim XP10, Sonim XP5plus, Sonim XP3plus, and Sonim XP Pro; Sonim mobile hotspot; industrial-grade accessories. It sells its mobile phones and accessories primarily to wireless carriers in the United States and Canada; and sells wireless carrier channels through distribution channels in North America and Europe. The company serves transportation and logistics, construction, manufacturing, facilities management, energy and utility, mining, and public safety sectors. The company was formerly known as NaviSpin.com, Inc. and changed its name to Sonim Technologies, Inc. in December 2001. Sonim Technologies, Inc. was incorporated in 1999 and is headquartered in San Diego, California. |
Akoya Biosciences, Inc. – SYM: AKYA Recent Price: $3.15
Takeover Action: Quanterix Corporation entered a merger agreement on January 10, 2025, to acquire Akoya Biosciences, Inc. in an all-stock deal valued at about $286.34 million. Under the terms of the agreement, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock they own, which is valued at approximately $3.73 per share. Description: Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. |
|
|
Our mailing address is:
DC2 Publishing LLC
4260 NW 1st Avenue Suite # 55
Boca Raton, FL 33431 - 4264 Daily Insider Trades
Copyright © 2024 DC2 Publishing LLC, All rights reserved.
You're receiving this email as part of your subscription to Daily Insider Trades. For more information about our privacy practices, please review our Privacy Policy or our Terms of Use.
|
|
|
|
